Development of a prognostic model of overall survival in oropharyngeal cancer from real-world data: PRO.M.E.THE.O.-Reference-Cited by-同舟云学术

Development of a prognostic model of overall survival in oropharyngeal cancer from real-world data: PRO.M.E.THE.O.

Published:2022-06 Issue:3 Volume:42 Page:205-214
ISSN:1827-675X
Container-title:Acta Otorhinolaryngologica Italica
language:
Short-container-title:Acta Otorhinolaryngol Ital

Author:

Miccichè Francesco,Chiloiro Giuditta,Longo Silvia,Autorino Rosa,Massaccesi Mariangela,Lenkowicz Jacopo,Bonomo Pierluigi,Desideri Isacco,Belgioia Liliana,Bacigalupo Almalina,D’Angelo Elisa,Bertolini Federica,Merlotti Anna,Denaro Nerina,Franco Pierfrancesco,Bussu Francesco,Paludetti Gaetano,Ricardi Umberto,Valentini Vincenzo

Publisher

Pacini Editore

Subject

Otorhinolaryngology,General Earth and Planetary Sciences,General Environmental Science

Reference24 articles.

1. Lacas B, Carmel A, Landais C, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiother Oncol 2021;156:281-293. https://doi.org/10.1016/j.radonc.2021.01.013

2. Blanchard P, Baujat B, Holostenco V, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol 2011;100:33-40. https://doi.org/10.1016/j.radonc.2011.05.036

3. Magrini SM, Buglione M, Corvò R, et al. Cetuximab and radiotherapy versus cisplatin and radiotherapy for locally advanced head and neck cancer: a randomized phase II trial. J Clin Oncol 2016;34:427-435. https://doi.org/10.1200/JCO.2015.63.1671

4. Mehanna H, Robinson M, Hartley A, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet 2019;393:51-60. https://doi.org/10.1016/S0140-6736(18)32752-1

5. Gillison ML, Trotti AM, Harris J, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet 2019;393:40-50. https://doi.org/10.1016/S0140-6736(18)32779-X